SGLT2-inhibitors are effective and safe in the elderly: The SOLD study
Maria Elena Lunati, Vincenzo Cimino, Alessandra Gandolfi, Matteo Trevisan, Laura Montefusco, Ida Pastore, Camilla Pace, Nazarena Betella, Giuseppe Favacchio, Monica Bulgheroni, Loredana Bucciarelli, Giulia Massari, Cristina Mascardi, Angela Girelli, Paola Silvia Morpurgo, Franco Folli, Livio Luzi, Marco Mirani, Basilio Pintaudi, Federico Bertuzzi, Cesare Berra, Paolo Fiorina
Topics & Concepts
MedicineEmpagliflozinDapagliflozinCanagliflozinInternal medicineDiabetes mellitusGlycated hemoglobinRenal functionAdverse effectPopulationHazard ratioMetforminBody mass indexType 2 diabetesInsulinConfidence intervalEndocrinologyEnvironmental healthDiabetes Treatment and ManagementChronic Kidney Disease and DiabetesDiabetes, Cardiovascular Risks, and Lipoproteins